Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 18.4%

Gross margin was 18.4% in Q1 FY2026, down 56.7 pp from a year earlier. On a trailing-twelve-month basis it was 75.0%, down 5.9 pp year over year. Over 3 fiscal years it widened by 24.2 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
18.4%-106.0 pp QoQ
Last fiscal yearDec 2025
81.5%-1.5 pp YoY
LTMMar 2026
75.0%-5.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-56.7 pp——
1 year-1.5 pp——
3 years+24.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
81.5%
Year-over-year change
-1.5pp

Gross Margin vs competitors

How DNA compares with its peers on the latest reported figures

  • DNA's LTM Mar 2026 gross margin of 75.0% is the 4th highest of the 7 companies compared; the peer median is 72.4%.
  • Its year-over-year change of -5.9 pp is the 6th highest of 7, against a peer median of +14.4 pp.
  • Over three fiscal years its change of +24.2 pp compares with a peer median of -2.0 pp.
DNA Competitors Peer median
Gross Margin for DNA and competitors
Company Period LTM level YoY 3-year change
VIRVir Biotechnology, Inc.LTM Mar 2026275.2% +2604.6 pp+21.4 pp
ARVNArvinas, Inc.LTM Mar 202697.4% -2.2 pp-2.0 pp
MGTXMeiraGTx Holdings plcLTM Mar 202691.6% +64.6 pp-6.0 pp
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 202675.0% -5.9 pp+24.2 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 202653.2% +23.4 pp—
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 202634.6% +5.5 pp-62.9 pp
VALNValneva SELTM Mar 202629.5% -17.1 pp+28.5 pp
MBXMBX Biosciences, Inc. Common StockFY2025— ——
REPLReplimune Group, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
Peer median (excluding DNA) 72.4%+14.4 pp-2.0 pp

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.